Shares of Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report) have been assigned an average rating of "Buy" from the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating, two have issued a buy rating and four have given a strong buy rating to the company.
A number of analysts have recently weighed in on the company. Sanford C. Bernstein upgraded Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Royal Bank Of Canada restated an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, July 25th.
Read Our Latest Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Stock Performance
Shares of Reckitt Benckiser Group stock traded down $0.05 on Monday, reaching $15.66. 170,919 shares of the company were exchanged, compared to its average volume of 351,906. The company has a quick ratio of 0.37, a current ratio of 0.56 and a debt-to-equity ratio of 1.01. The company's 50-day moving average is $14.75 and its two-hundred day moving average is $13.83. Reckitt Benckiser Group has a 1-year low of $11.73 and a 1-year high of $15.82.
Reckitt Benckiser Group Cuts Dividend
The firm also recently announced a dividend, which will be paid on Thursday, September 25th. Investors of record on Monday, August 11th will be given a $0.2106 dividend. This represents a yield of 341.0%. The ex-dividend date is Friday, August 8th.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
See Also

Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.